April 7, 2015 | Medical equipment giant Medtronic has invested $2 million in DreaMed Diabetes, an Israeli startup company that develops a new delivery system of insulin. DreaMed has signed an exclusive development and license agreement with Medtronic for the development and marketing of products incorporating DreaMed’s technology in Medtronic’s insulin pumps. DreaMed was founded in 2014 by Eran Atlas and Shahar Miller.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments